Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects
Status:
Completed
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
The bioavailability of Irbesartan (150 mg) developed by Shenzhen Haibin Pharmaceutical Co.,
Ltd. was compared with that of reference Irbesartan (Aprovel ®,150 mg) produced by Sanofi
Clir SNC. The bioequivalence of single dose of test preparation and reference preparation was
evaluated in heathy subjects under fasting and fed conditions.